GlassScriptPhysician profile
Morris J Kliger
NPI 1124080817
$2,460.23
in general payments reported to CMS, 2019-2025
31 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $143 · 2021: $402 · 2022: $280 · 2023: $335 · 2024: $283 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $314.30 | 2019-2024 | |
| Pfizer INC. | $311.50 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $215.24 | 2019-2022 | |
| Akcea Therapeutics, INC. | $166.72 | 2019 | |
| Glaxosmithkline, LLC. | $165.58 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $155.47 | 2019-2025 | Wegovy |
| Janssen Biotech, INC. | $115.00 | 2025 | Tremfya, Simponi Aria |
| Abbott Laboratories | $97.97 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $89.22 | 2019-2024 | Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $88.57 | 2019-2022 | |
| Lilly USA, LLC | $85.89 | 2020-2024 | Jardiance, Mounjaro |
| Dexcom, INC. | $82.57 | 2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $55.83 | 2019-2020 | |
| Amgen INC. | $54.25 | 2024-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $53.26 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $51.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $44.05 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.27 | 2022-2023 | |
| Daiichi Sankyo INC. | $37.04 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.48 | 2019 | |
| Verona Pharma, INC. | $28.04 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $26.13 | 2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $24.95 | 2024 | Ultomiris |
| Idorsia Pharmaceuticals US INC | $21.35 | 2022 | |
| Ibsa Pharma INC. | $20.49 | 2019 | |
| Seqirus USA INC | $19.79 | 2021 | |
| Pulmonx Corporation | $18.62 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Tolmar, INC. | $13.48 | 2023 | |
| Sanofi-Aventis U.S. LLC | $13.31 | 2020 | |
| Horizon Therapeutics Plc | $12.41 | 2019 | |
| Dynavax Technologies Corporation | $9.76 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Kliger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.